How to Get Leqvio (Inclisiran) in New Jersey

What Is Leqvio and Why Is It Prescribed?

Leqvio is a small-interfering RNA (siRNA) therapy that silences the gene encoding PCSK9, a protein that degrades LDL receptors in the liver. By reducing PCSK9, the drug keeps more LDL receptors on hepatocyte surfaces, which pulls more LDL-C out of circulation. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins [1].

The key ORION-10 trial (N=1,561, statin-treated ASCVD patients) found that inclisiran 284 mg subcutaneous injection reduced LDL-C by 51% from baseline at day 510 compared with a 0.5% reduction in the placebo arm (P<0.001) [2]. The companion ORION-11 trial (N=1,617) confirmed nearly identical results in a broader ASCVD and ASCVD-risk-equivalent population, with a 49.9% LDL-C reduction at day 510 (P<0.001) [2]. Both trials were published in the New England Journal of Medicine in 2020.

Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab (Repatha) or alirocumab (Praluent), inclisiran is dosed only twice yearly after two loading injections, which dramatically reduces the administration burden [3]. That twice-yearly schedule makes telehealth-coordinated care particularly practical for New Jersey patients who can receive the injection at a local clinician's office or infusion suite.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD who are on maximally tolerated statin therapy and have LDL-C levels persistently above 70 mg/dL, PCSK9 inhibitors represent a Class I recommendation to further reduce cardiovascular risk." [4] Inclisiran falls within this PCSK9-targeting class.

Who Qualifies for a Leqvio Prescription in New Jersey?

Qualification follows the FDA label and payer criteria. Most New Jersey insurers, including NJ FamilyCare (Medicaid) and major commercial carriers, require at least one of the following [1][5]:

• Diagnosed HeFH confirmed by genetic testing or Dutch Lipid Clinic Network score of 6 or above.
• Established ASCVD, defined as prior myocardial infarction, stroke, peripheral arterial disease, or coronary revascularization.
• LDL-C remaining above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH) despite maximally tolerated statin therapy, with or without ezetimibe.

Patients with homozygous FH (HoFH) are not covered under the current FDA label for inclisiran, which specifies HeFH only [1]. Clinicians sometimes request off-label coverage for HoFH through exception pathways, though approval rates are lower.

The ACC recommends that patients with LDL-C above 190 mg/dL who have an inadequate response to high-intensity statins be considered for PCSK9 inhibition regardless of a formal ASCVD diagnosis [4]. New Jersey commercial payers generally accept this framing when the prior authorization documents adequate statin trial duration (typically 90 days or more at maximum tolerated dose).

Which Providers Can Prescribe Leqvio in New Jersey?

In New Jersey, Leqvio may be prescribed by any licensed prescriber with authority to write controlled and non-controlled prescription drugs. That includes:

MDs and DOs. Cardiologists, preventive cardiologists, and lipidologists most commonly initiate Leqvio, but any MD or DO in New Jersey with prescribing authority may write the script [6].

Nurse Practitioners. New Jersey is a full-practice-authority state for NPs under N.J.S.A. 45:11-49, meaning NPs may diagnose, treat, and prescribe, including specialty drugs, without a physician collaborative agreement [6]. This is directly relevant for telehealth platforms staffed by NPs.

Physician Assistants. PAs in New Jersey prescribe under a delegation agreement with a supervising physician. Within that agreement, a PA may prescribe Leqvio [6].

Telehealth providers operating in New Jersey must hold an active New Jersey license. The New Jersey Division of Consumer Affairs enforces this rule, and patients should verify licensure before booking a telehealth visit [7].

How Telehealth Works for Leqvio in New Jersey

New Jersey permits synchronous telehealth visits (video or phone) for prescription of non-controlled specialty medications, including inclisiran [7]. A new patient does not need a prior in-person visit to establish care with a telehealth provider for Leqvio, provided the clinician can conduct a clinically adequate evaluation, review lab results, and document the qualifying diagnosis.

The standard telehealth workflow runs as follows:

1. Patient completes an intake form including cardiovascular history, current medications, and recent lipid panel results.
2. A licensed New Jersey clinician conducts a synchronous video visit (typically 20 to 40 minutes for a new patient).
3. The clinician documents the qualifying diagnosis, prior statin trial, and LDL-C level.
4. A prescription and prior authorization packet are submitted to the patient's insurer or to Novartis's patient-support program (Leqvio Together).
5. Upon approval, the specialty pharmacy ships the drug to a designated administration site.
6. The patient receives the subcutaneous injection at an in-office or infusion-center visit.

Because inclisiran is not approved for self-injection, the telehealth model covers the prescribing and coordination steps. The injection itself always requires an in-person clinical encounter [1].

What Labs Are Required Before Starting Leqvio in New Jersey?

Baseline labs are both clinically necessary and typically required by payers for prior authorization documentation [4][5].

Fasting lipid panel. A fasting lipid panel measuring total cholesterol, LDL-C, HDL-C, and triglycerides is the cornerstone requirement. Most payers want a result dated within 90 days of the PA submission. The LDL-C value must meet the threshold specified in the payer's coverage policy (commonly above 70 mg/dL for ASCVD or above 100 mg/dL for HeFH) [5].

Hepatic function panel. Because inclisiran is processed by the liver, a baseline AST and ALT measurement is standard clinical practice before initiation, though the FDA label does not mandate dose adjustment for mild-to-moderate hepatic impairment [1]. Severe hepatic impairment (Child-Pugh C) has not been studied.

Renal function. The ORION trials enrolled patients with eGFR as low as 15 mL/min/1.73 m², and inclisiran pharmacokinetics are not meaningfully altered by renal disease. Still, a baseline creatinine and eGFR give the prescriber a complete metabolic picture and are often requested by payers [2][8].

Documentation of prior statin trial. Lab evidence of LDL-C on statin therapy, plus pharmacy records or clinical notes confirming the statin dose and duration, satisfies the prior statin trial requirement. Most New Jersey payers require at least 90 consecutive days on a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) [5].

Optional: genetic or clinical FH score. For HeFH-pathway PAs, a Dutch Lipid Clinic Network score of 6 or above, or documentation of a pathogenic LDL receptor variant, strengthens the application [9].

Prior Authorization in New Jersey: What the Process Actually Looks Like

Prior authorization is required by virtually every commercial and public payer covering New Jersey patients. NJ FamilyCare Medicaid covers inclisiran for FH and ASCVD indications with PA [5]. Major commercial carriers, Horizon BCBS NJ, Aetna NJ, Cigna, UnitedHealthcare, each maintain their own PA criteria, but the documentation requirements follow a consistent pattern [10].

A complete PA submission for Leqvio in New Jersey generally includes:

• Signed prescriber letter of medical necessity.
• Fasting LDL-C result (within 90 days) showing LDL-C above the threshold.
• Diagnosis code (E78.01 for HeFH, or an appropriate ASCVD ICD-10 code such as I25.10).
• Evidence of adequate statin trial: pharmacy fill records or office notes confirming dose and duration.
• Documentation that the patient is on maximally tolerated statin therapy.
• For HeFH cases: genetic or clinical score documentation [9].

PA turnaround in New Jersey averages 5 to 14 business days for standard requests. Urgent PA requests, available when a patient has recently survived an acute coronary event, may be processed within 72 hours under NJ insurance regulations [10].

Novartis's Leqvio Together program can submit the PA on behalf of the prescribing clinician at no charge, which shortens administrative time considerably [11]. The program also coordinates specialty pharmacy delivery and offers a copay card that reduces out-of-pocket cost to $0 for eligible commercially insured patients [11].

Specialty Pharmacy and Administration in New Jersey

Leqvio is a buy-and-bill drug distributed through a specialty pharmacy network. In New Jersey, specialty pharmacies contracted by Novartis ship the drug directly to the prescriber's office or infusion center, not to the patient's home. The prescriber administers the 1.5 mL subcutaneous injection in the abdomen, upper arm, or thigh [1].

503A compounding pharmacies. Some patients ask whether a 503A compounding pharmacy in New Jersey can prepare inclisiran at lower cost. The answer is technically yes under New Jersey's 503A licensing framework, but there are meaningful caveats. Inclisiran sodium is a complex siRNA molecule. No 503A pharmacy has publicly demonstrated the bioequivalence and stability data required to replicate Novartis's manufacturing process. The FDA has not listed inclisiran on the 503B bulk drug list [12]. Any compounded version would lack the clinical trial data from ORION-10 and ORION-11. HealthRX's clinical team does not recommend compounded inclisiran at this time given the absence of quality and efficacy verification.

Administration schedule. The FDA-approved schedule is: Day 1 (first injection), Day 90 (second injection), then every 6 months thereafter [1]. Missing an injection by up to 3 months is acceptable per the label; if more than 3 months pass, the clinician restarts the two-injection loading sequence.

How Long Does It Take to Get Leqvio After Your First Appointment in New Jersey?

The timeline from first consult to first injection varies by payer speed and specialty pharmacy logistics. A reasonable estimate by step:

• Telehealth or in-person consult: Day 1.
• Lab draw (if not already done): Day 1 to 3.
• PA submission: Day 2 to 5.
• PA decision: Day 7 to 19 (standard), Day 3 to 5 (urgent).
• Specialty pharmacy processing and shipping: 3 to 7 business days after approval.
• First injection appointment: typically 2 to 6 weeks from initial consult.

Patients who already have recent qualifying labs and clear ASCVD documentation may reach first injection in under 3 weeks [10][11].

Can You Transfer a Leqvio Prescription to New Jersey?

Yes. If a patient has an active Leqvio prescription from another state and moves to New Jersey, the original prescriber can transfer the prescription to a New Jersey-licensed specialty pharmacy, provided the prescriber holds a valid New Jersey telehealth or in-person license, or the patient establishes care with a new New Jersey prescriber [7]. If the out-of-state prescriber is not licensed in New Jersey, the patient needs a new evaluation with a New Jersey-licensed clinician before the drug can be dispensed through a New Jersey-contracted pharmacy.

For Novartis's Leqvio Together program, a change of administration site, for example, from an out-of-state cardiologist's office to a New Jersey office or infusion center, is handled by calling the program's coordination line. No new full PA is required if the same insurer and diagnosis remain unchanged, though the new New Jersey prescriber must co-sign the updated prescription [11].

Cost and Coverage in New Jersey

Without insurance, the list price of Leqvio in the United States is approximately $3,500 per injection, or $6,800 to $7,000 per year for the maintenance two-injection annual schedule. With prior authorization, most commercial plans cover Leqvio at a specialty tier copay [11].

NJ FamilyCare (New Jersey's Medicaid program) covers inclisiran for FH and established ASCVD with prior authorization. The covered diagnosis codes are E78.01 (HeFH), I25.10, I63.x (stroke), and similar ASCVD codes [5]. Medicaid members typically pay $0 or a minimal copay once PA is granted.

Medicare Part B covers Leqvio as a physician-administered drug under the buy-and-bill model [13]. The patient is responsible for 20% coinsurance after the Part B deductible unless they carry supplemental coverage. Novartis's copay assistance program does not apply to Medicare beneficiaries under federal anti-kickback rules [11].

The ORION-4 trial (ongoing, N=15,000+, NCT04929979) is evaluating whether inclisiran reduces major adverse cardiovascular events in a broad secondary prevention population [14]. Positive cardiovascular outcome data from ORION-4 may expand coverage criteria and reduce PA burden in future New Jersey payer policy updates.

Side Effects and Safety Profile Relevant to New Jersey Patients

In the pooled ORION-10 and ORION-11 data, inclisiran was well tolerated. The most common adverse event was injection-site reaction (8.2% inclisiran vs. 1.8% placebo), typically mild erythema or discomfort resolving within 1 to 2 days [2]. Myalgia and myopathy rates were not elevated above placebo (1.4% vs. 1.5%), which is a relevant distinction for patients who have discontinued statins due to muscle side effects [2].

Liver enzyme elevations above 3x the upper limit of normal occurred in 2.5% of inclisiran patients vs. 1.6% in placebo groups; none resulted in hepatic failure in the trial population [2][8]. New Jersey prescribers typically recheck a hepatic panel at the 3-month follow-up injection visit.

The American College of Cardiology notes that inclisiran's safety profile across ORION trials supports its use in statin-intolerant patients, though formal FDA labeling for statin intolerance as a standalone indication remains pending [4][15].

Finding a Leqvio Provider in New Jersey: Practical Steps

New Jersey has a dense network of cardiologists and lipid specialists who prescribe Leqvio, concentrated in the northern NJ/New York metro corridor and in the Camden/Philadelphia border region. For patients who prefer telehealth:

1. Confirm the telehealth provider holds an active New Jersey license (searchable at the NJ Division of Consumer Affairs provider lookup at njconsumeraffairs.gov).
2. Verify the platform employs a clinician with cardiology or lipidology training, or that a consulting cardiologist reviews the case.
3. Ask whether the practice uses Novartis's Leqvio Together hub for PA submission.
4. Confirm the administration site (infusion center or physician office) is within reasonable travel distance, since injections occur twice yearly after the loading phase.
5. Request that all prior authorization documents be sent to you as well, so you can monitor the timeline independently.

The Leqvio Together support line is 1-833-LEQVIO-1 (1-833-537-8461). Novartis case managers can identify contracted administration sites in your New Jersey zip code and coordinate delivery directly [11].

Patients with an LDL-C above 70 mg/dL on maximally tolerated statin therapy and a prior MI, stroke, or coronary stent should schedule a lipid-focused visit without delay. The 2022 ACC/AHA Cholesterol Guideline gives PCSK9 inhibitor therapy a Class I recommendation in this population, meaning the evidence supports its use without reservation [4].